Market closedNon-fractional
MiMedx Group/MDXG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About MiMedx Group
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Ticker
MDXG
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Marietta, United States
Employees
895
Website
www.mimedx.com
MiMedx Group Metrics
BasicAdvanced
$1.1B
Market cap
17.37
P/E ratio
$0.44
EPS
1.43
Beta
-
Dividend rate
Price and volume
Market cap
$1.1B
Beta
1.43
Financial strength
Current ratio
3.289
Quick ratio
2.499
Long term debt to equity
11.849
Total debt to equity
12.491
Interest coverage (TTM)
7.55%
Management effectiveness
Return on assets (TTM)
16.26%
Return on equity (TTM)
68.13%
Valuation
Price to earnings (TTM)
17.374
Price to revenue (TTM)
2.869
Price to book
7.28
Price to tangible book (TTM)
9.17
Price to free cash flow (TTM)
27.985
Growth
Revenue change (TTM)
19.20%
Earnings per share change (TTM)
-259.85%
3-year revenue growth (CAGR)
10.72%
3-year earnings per share growth (CAGR)
-18.43%
What the Analysts think about MiMedx Group
Analyst Ratings
Majority rating from 5 analysts.
MiMedx Group Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$85M
-2.42%
Net income
$9.2M
-82.77%
Profit margin
10.86%
-82.35%
MiMedx Group Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-
$0.06
$0.32
$0.07
-
Expected
-$0.02
$0.05
$0.07
$0.05
$0.08
Surprise
-
33.33%
357.14%
55.56%
-
MiMedx Group News
AllArticlesVideos
MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports
GlobeNewsWire·4 days ago
MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer
GlobeNewsWire·4 weeks ago
MIMEDX to Participate in Upcoming Investor Conferences
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MiMedx Group stock?
MiMedx Group (MDXG) has a market cap of $1.1B as of July 26, 2024.
What is the P/E ratio for MiMedx Group stock?
The price to earnings (P/E) ratio for MiMedx Group (MDXG) stock is 17.37 as of July 26, 2024.
Does MiMedx Group stock pay dividends?
No, MiMedx Group (MDXG) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next MiMedx Group dividend payment date?
MiMedx Group (MDXG) stock does not pay dividends to its shareholders.
What is the beta indicator for MiMedx Group?
MiMedx Group (MDXG) has a beta rating of 1.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell MiMedx Group stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.